Skip to content

Study · Animal study (in vivo) · rat · 2013

3 results

[The effect of semax and its C-end peptide PGP on Vegfa gene expression in the rat brain during incomplete global ischemia].

Stavchanskiĭ VV, Tvorogova TV, Botsina AIu, Limborskaia SA, Skvortsova VI, Miasoedov NF, Dergunova LV

Molekuliarnaia biologiia1 May 2013Cited by 4 (Europe PMC)

PMID23888777 (opens in a new tab)DOI10.7868/s0026898413030166 (opens in a new tab)PepBankPUB-23888777
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats with incomplete global ischemia, semax reduced Vegfa mRNA levels in the frontal cortex at 4, 8 and 12 h after occlusion.

    In plain wordsIn rats with brain ischemia, Semax lowered the activity of the VEGFA gene in the frontal cortex at 4, 8 and 12 hours.

    Peptide
    Semax
    Outcome
    DecreaseVegfa mRNA in frontal cortex
    Study

    ratn: not reported in source

    Incomplete global ischemia (common carotid artery occlusion)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semax treatment reduces Vegfa mRNA levels in the frontal cortex (4, 8 and 12 h after the occlusion) and hippocampus of ischemic rats (2 and 4 h).
    1 context sentence
    Summary · context
    Here we have analyzed the effects of semax and its C-terminal Pro-Gly-Pro tripeptide upon Vegfa mRNA expression in different rat brain regions after common carotid artery occlusion.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with incomplete global ischemia, semax reduced Vegfa mRNA levels in the hippocampus at 2 and 4 h after occlusion.

    In plain wordsIn rats with brain ischemia, Semax lowered the activity of the VEGFA gene in the hippocampus at 2 and 4 hours.

    Peptide
    Semax
    Outcome
    DecreaseVegfa mRNA in hippocampus (2 and 4 h)
    Study

    ratn: not reported in source

    Incomplete global ischemia (common carotid artery occlusion)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semax treatment reduces Vegfa mRNA levels in the frontal cortex (4, 8 and 12 h after the occlusion) and hippocampus of ischemic rats (2 and 4 h).
    1 context sentence
    Summary · context
    Here we have analyzed the effects of semax and its C-terminal Pro-Gly-Pro tripeptide upon Vegfa mRNA expression in different rat brain regions after common carotid artery occlusion.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats with incomplete global ischemia, Vegfa mRNA in the hippocampus was increased at 24 h after occlusion with semax, possibly reflecting neuroprotective properties.

    In plain wordsIn rats with brain ischemia, VEGFA gene activity in the hippocampus was higher at 24 hours with Semax, which may reflect protection.

    Peptide
    Semax
    Outcome
    IncreaseVegfa mRNA in hippocampus (24 h)
    Study

    ratn: not reported in source

    Incomplete global ischemia (common carotid artery occlusion)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, increase in the level of mRNA Vegfa in the hippocampus (24 h after occlusion) perhaps reflects neuroprotective properties of this drug.
    1 context sentence
    Summary · context
    Here we have analyzed the effects of semax and its C-terminal Pro-Gly-Pro tripeptide upon Vegfa mRNA expression in different rat brain regions after common carotid artery occlusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.